NASDAQ:BRNS Barinthus Biotherapeutics Q2 2026 Earnings Report $0.74 0.00 (0.00%) As of 09/18/2026 ProfileEarnings HistoryForecast Barinthus Biotherapeutics EPS ResultsActual EPS-$0.26Consensus EPS -$0.28Beat/MissBeat by +$0.02One Year Ago EPSN/ABarinthus Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABarinthus Biotherapeutics Announcement DetailsQuarterQ2 2026Date8/7/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsBarinthus Biotherapeutics' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Barinthus Biotherapeutics Earnings HeadlinesBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsAugust 24, 2026 | globenewswire.comBarinthus Biotherapeutics PLC ADR BRNSJuly 3, 2026 | morningstar.comMThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 19 at 1:00 AM | Chaikin Analytics (Ad)Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSMay 11, 2026 | businesswire.comBarinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | finanznachrichten.deBarinthus in Green on Bringing Out Quarterly NumbersApril 30, 2026 | baystreet.caSee More Barinthus Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Barinthus Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your email. Email Address About Barinthus BiotherapeuticsBarinthus Biotherapeutics (NASDAQ:BRNS) plc is a clinical-stage biopharmaceutical company developing T-cell immunotherapies for autoimmune diseases. The company’s approach is designed to selectively modulate disease-causing immune responses while preserving normal immune function. Its lead programs include VTP-1000, an investigational therapy being developed for celiac disease, and VTP-300, an immunotherapy candidate for chronic hepatitis B virus infection. Barinthus also maintains a broader pipeline of T-cell therapies based on its proprietary SNAP-T and TRi-STAR platforms, which are intended to generate targeted and durable immune responses. Headquartered in the United Kingdom, Barinthus conducts research and clinical development activities internationally. The company was previously known as Barinthus Therapeutics plc and is led by Chief Executive Officer William Enright. Its ordinary shares trade on the Nasdaq Global Select Market under the symbol BRNS.View Barinthus Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
